Author: Wurm, Hannah; Attfield, Kate; Iversen, Astrid KN; Gold, Ralf; Fugger, Lars; Haghikia, Aiden
Title: Recovery from COVID-19 in a B-cell-depleted multiple sclerosis patient Cord-id: enkxwg31 Document date: 2020_8_7
ID: enkxwg31
Snippet: Approximately 200,000 multiple sclerosis (MS) patients worldwide receive B-cell-depleting immunotherapy with rituximab (anti-CD20), which eliminates the ability to generate an antibody response to new infections. As severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)–specific antibodies might help viral clearance, these patients could be at risk of severe complications if infected. Here, we report on an MS patient who had received rituximab for ~3 years. The patient was examined 5 day
Document: Approximately 200,000 multiple sclerosis (MS) patients worldwide receive B-cell-depleting immunotherapy with rituximab (anti-CD20), which eliminates the ability to generate an antibody response to new infections. As severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)–specific antibodies might help viral clearance, these patients could be at risk of severe complications if infected. Here, we report on an MS patient who had received rituximab for ~3 years. The patient was examined 5 days before the onset of coronavirus disease 2019 (COVID-19) symptoms and was admitted to the hospital 2 days after. She recovered 14 days after symptom onset despite having a 0% B lymphocyte count and not developing SARS-CoV-2 immunoglobulin G (IgG) antibodies.
Search related documents:
Co phrase search for related documents- low oxygen saturation and lymphocyte count: 1, 2, 3, 4, 5, 6, 7, 8
- lung ultrasound and lymphocyte count: 1, 2
- lung ultrasound and magnetic resonance: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13
- lung volume and lymphocyte count: 1, 2
- lung volume and magnetic resonance: 1, 2
- lymphocyte count and magnetic resonance: 1, 2
Co phrase search for related documents, hyperlinks ordered by date